Profile of Multisystem Inflammatory Syndrome in Children (MIS-C) in Infants in North India during the Second Wave of SARS-CoV-2 Pandemic

Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All se...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of medical specialities Vol. 15; no. 3; pp. 145 - 151
Main Authors Kumar, Ashna, Maheshwari, Anu, Mahajan, Akanksha, Mahto, Deonath, Sehgal, Suchitra, Basu, Srikanta
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow 01.07.2024
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Edition2
Subjects
Online AccessGet full text
ISSN0976-2884
0976-2892
DOI10.4103/injms.injms_196_23

Cover

Abstract Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75th, 0.5-3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome.
AbstractList Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75th, 0.5-3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome.
Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. A total of 19 infants were studied. Thirteen (68.3) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75[sup.th], 0.5-3). The most common presenting symptoms were fever (68.4), gastrointestinal complaints (63.1), and edema (36.8). Other predominant signs were shock (78.9), myocarditis (52.6), and neurological complaints (26.3). Incomplete KD was present in 21 of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100), 31.5 received a second dose of IVIG, and 63.1 received pulse intravenous methylprednisolone. A total of 5 (26.3) died as a result of the disease process. The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome.
Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3%) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25–75th, 0.5–3). The most common presenting symptoms were fever (68.4%), gastrointestinal complaints (63.1%), and edema (36.8%). Other predominant signs were shock (78.9%), myocarditis (52.6%), and neurological complaints (26.3%). Incomplete KD was present in 21% of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100%), 31.5% received a second dose of IVIG, and 63.1% received pulse intravenous methylprednisolone. A total of 5 (26.3%) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome.
Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children, adolescents, and adults but also infants, more so during the second wave of the global pandemic. Materials and Methods: All sequentially admitted infants hospitalized during 6 months who fulfilled the World Health Organization criteria for MIS-C or American Heart Association 2017 criteria for Kawasaki disease (KD) (and positive coronavirus disease-2019 [COVID-19] serology) were included in the present study. Results: A total of 19 infants were studied. Thirteen (68.3) had evidence of recent COVID-19 infection. The median age of presentation was 2 months (interquartile range 25-75[sup.th], 0.5-3). The most common presenting symptoms were fever (68.4), gastrointestinal complaints (63.1), and edema (36.8). Other predominant signs were shock (78.9), myocarditis (52.6), and neurological complaints (26.3). Incomplete KD was present in 21 of patients. Elevated C-reactive protein, ferritin, D-Dimer, N-terminal prohormone of brain natriuretic peptide, and reduced fibrinogen were markers of severe illness. All subjects received intravenous immunoglobulin (IVIG) (100), 31.5 received a second dose of IVIG, and 63.1 received pulse intravenous methylprednisolone. A total of 5 (26.3) died as a result of the disease process. Conclusion: The spectrum of MIS-C in infants can be varied and is different from older children. A high index of suspicion is therefore needed in infants who present with critical illness and do not respond appropriately to conventional antibiotics and supportive care. The addition of IVIG and corticosteroids to the treatment regimen leads to a favorable outcome. Keywords: Immunomodulation, intravenous immunoglobulin, Kawasaki disease, multisystem inflammatory syndrome in children
Audience Academic
Author Kumar, Ashna
Mahto, Deonath
Sehgal, Suchitra
Basu, Srikanta
Maheshwari, Anu
Mahajan, Akanksha
Author_xml – sequence: 1
  givenname: Ashna
  surname: Kumar
  fullname: Kumar, Ashna
– sequence: 2
  givenname: Anu
  surname: Maheshwari
  fullname: Maheshwari, Anu
  email: dranugulati@gmail.com
– sequence: 3
  givenname: Akanksha
  surname: Mahajan
  fullname: Mahajan, Akanksha
– sequence: 4
  givenname: Deonath
  surname: Mahto
  fullname: Mahto, Deonath
– sequence: 5
  givenname: Suchitra
  surname: Sehgal
  fullname: Sehgal, Suchitra
– sequence: 6
  givenname: Srikanta
  surname: Basu
  fullname: Basu, Srikanta
BookMark eNp9Ut1u0zAYjdCQGGMvwJUlbuAiJY4dO76sKgaVNjZRfi4tx_7cuktsZKdUfQMeG7cZE0gIW7I_HZ1z_HO-58WZDx6K4iWuZhRX5K3z2yHNTqvEgsmaPCnOK8FZWbeiPnusW_qsuExpW-VBhGCkOi9-3sVgXQ8oWHSz60eXDmmEAS297dUwqDHEA1odvIlhAOQ8WmxcbyJ49PpmuSoXb45YJis_pmP5McRxkwHjFDK76PwajRtAK9DBG_RN_TidtJp_ytrwtazRnfIGBqdfFE-t6hNcPuwXxZerd58XH8rr2_fLxfy61ITzVLLGCoyJwKTVYCjFrKKmxbrhFdE10Qa0MqQxDalBgWgsq2kLlDLccNMaQi6K5eRrgtrK79ENKh5kUE6egBDXUsXR6R5kxetOddACMEs7EF1rOdOaYqO45Z3JXq8mr7XKdOdtGKPSg0tazlssGiaY4Jk1-wcrz9O7c5TH__9bUE8CHUNKEezjNXElj4nLKes_E8-i20m0D_0IMd33uz1EOYC592H_H6XEtJEPXSCDlb-7gPwCml6_ww
Cites_doi 10.1001/jamapediatrics.2021.0038
10.1016/S0140-6736(20)31103-X
10.1056/NEJMoa2021756
10.1002/art.39332
10.1002/jmv.26951
10.1161/CIR.0000000000000484
10.1001/jama.2021.2091
10.1111/1756-185X.12854
10.3345/cep.2021.00913
10.5114/reum.2021.102871
10.3389/fped.2020.593455
10.1097/INF.0000000000003149
10.15585/mmwr.mm6932e2
10.1111/jpc.15675
10.1001/jamapediatrics.2021.0630
ContentType Journal Article
Copyright Copyright: © 2024 Indian Journal of Medical Specialities
COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd.
Copyright_xml – notice: Copyright: © 2024 Indian Journal of Medical Specialities
– notice: COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd.
DBID AAYXX
CITATION
DOA
DOI 10.4103/injms.injms_196_23
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 0976-2892
Edition 2
EndPage 151
ExternalDocumentID oai_doaj_org_article_072babe8ee6f4be9b8f76cc41da7f7bd
A819569697
10_4103_injms_injms_196_23
IMSP-15-145
GeographicLocations United States
India
GeographicLocations_xml – name: India
– name: United States
GroupedDBID 0R~
4.4
457
53G
AALRI
AAWTL
AAXUO
ACGFS
ADBBV
AEGXH
AITUG
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BELOY
C1A
DIK
EBS
EIHBH
EJD
FDB
GX1
H13
IAO
IHR
INH
ITC
O9-
OK1
OVD
RMW
RNS
ROL
TEORI
W3E
AAYXX
ADJBI
CITATION
GROUPED_DOAJ
ID FETCH-LOGICAL-c377s-65f91139138ced441604d81c5703c23cdecad35d532eae95f6248e446157d8d33
IEDL.DBID DOA
ISSN 0976-2884
IngestDate Mon Sep 08 19:52:56 EDT 2025
Tue Jun 17 22:02:10 EDT 2025
Tue Jun 10 21:01:10 EDT 2025
Tue Jul 01 01:41:05 EDT 2025
Wed May 28 23:14:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Kawasaki disease
multisystem inflammatory syndrome in children
Immunomodulation
intravenous immunoglobulin
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c377s-65f91139138ced441604d81c5703c23cdecad35d532eae95f6248e446157d8d33
OpenAccessLink https://doaj.org/article/072babe8ee6f4be9b8f76cc41da7f7bd
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_072babe8ee6f4be9b8f76cc41da7f7bd
gale_infotracmisc_A819569697
gale_infotracacademiconefile_A819569697
crossref_primary_10_4103_injms_injms_196_23
wolterskluwer_medknow_10_4103_injms_injms_196_23_145_Profile_of_Multisys
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-01
  day: 01
PublicationDecade 2020
PublicationPlace India
PublicationPlace_xml – name: India
PublicationTitle Indian journal of medical specialities
PublicationYear 2024
Publisher Wolters Kluwer - Medknow
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer Medknow Publications
Publisher_xml – name: Wolters Kluwer - Medknow
– name: Medknow Publications and Media Pvt. Ltd
– name: Wolters Kluwer Medknow Publications
References Zhao (R17-20240903) 2021; 93
Hobbs (R4-20240903) 2020; 8
Kok (R16-20240903) 2021; 64
Godfred-Cato (R9-20240903) 2020; 69
Godfred-Cato (R11-20240903) 2021; 40
Flannery (R21-20240903) 2021; 175
Dufort (R3-20240903) 2020; 383
Pawar (R20-20240903) 2021; 8
Belay (R19-20240903) 2021; 175
Feldstein (R18-20240903) 2021; 325
Verdoni (R2-20240903) 2020; 395
Maheshwari (R10-20240903) 2022; 58
McCrindle (R12-20240903) 2017; 135
Poniecka (R5-20240903) 2021; 59
Singh (R13-20240903) 2016; 19
Ravelli (R15-20240903) 2016; 68
References_xml – volume: 175
  start-page: 594
  year: 2021
  ident: R21-20240903
  article-title: Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2021.0038
– volume: 395
  start-page: 1771
  year: 2020
  ident: R2-20240903
  article-title: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic:an observational cohort study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31103-X
– volume: 383
  start-page: 347
  year: 2020
  ident: R3-20240903
  article-title: Multisystem inflammatory syndrome in children in New York state
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2021756
– volume: 68
  start-page: 566
  year: 2016
  ident: R15-20240903
  article-title: 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis:A European league against rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organization Collaborative Initiative
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39332
– volume: 93
  start-page: 4358
  year: 2021
  ident: R17-20240903
  article-title: The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19:A meta-analysis
  publication-title: J Med Virol
  doi: 10.1002/jmv.26951
– volume: 135
  start-page: e927
  year: 2017
  ident: R12-20240903
  article-title: Diagnosis, treatment, and long-term management of Kawasaki disease:A scientific statement for health professionals from the American Heart Association
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000484
– volume: 325
  start-page: 1074
  year: 2021
  ident: R18-20240903
  article-title: Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19
  publication-title: JAMA
  doi: 10.1001/jama.2021.2091
– volume: 19
  start-page: 924
  year: 2016
  ident: R13-20240903
  article-title: Kawasaki disease in infants below 6 months:A clinical conundrum?
  publication-title: Int J Rheum Dis
  doi: 10.1111/1756-185X.12854
– volume: 8
  start-page: 572
  year: 2021
  ident: R20-20240903
  article-title: Neonatal Multisystem Inflammatory Syndrome (MIS-N) associated with prenatal maternal SARS-CoV-2:A case series
  publication-title: Children (Basel)
– volume: 64
  start-page: 599
  year: 2021
  ident: R16-20240903
  article-title: Multisystem inflammatory syndrome in children and Kawasaki disease in infants:2 sides of the same coin?
  publication-title: Clin Exp Pediatr
  doi: 10.3345/cep.2021.00913
– volume: 59
  start-page: 47
  year: 2021
  ident: R5-20240903
  article-title: A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children –Literature review based on two case reports
  publication-title: Reumatologia
  doi: 10.5114/reum.2021.102871
– volume: 8
  start-page: 593455
  year: 2020
  ident: R4-20240903
  article-title: COVID-19 in children:A review and parallels to other hyperinflammatory syndromes
  publication-title: Front Pediatr
  doi: 10.3389/fped.2020.593455
– volume: 40
  start-page: 601
  year: 2021
  ident: R11-20240903
  article-title: Multisystem inflammatory syndrome in Infants <12 months of age, United States, May 2020-January 2021
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/INF.0000000000003149
– volume: 69
  start-page: 1074
  year: 2020
  ident: R9-20240903
  article-title: COVID-19-Associated multisystem inflammatory syndrome in children –United States, March-July 2020
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6932e2
– volume: 58
  start-page: 136
  year: 2022
  ident: R10-20240903
  article-title: Comparison of clinical and laboratory profile of survivors and non-survivors of SARS-CoV-2-related multisystem inflammatory syndrome of childhood in India:An observational study
  publication-title: J Paediatr Child Health
  doi: 10.1111/jpc.15675
– volume: 175
  start-page: 837
  year: 2021
  ident: R19-20240903
  article-title: Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic
  publication-title: JAMA Pediatr
  doi: 10.1001/jamapediatrics.2021.0630
SSID ssj0000399630
Score 2.2649667
Snippet Abstract Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only...
Background: Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older...
Multisystem inflammatory syndrome in children (MIS-C) secondary to severe acute respiratory syndrome coronavirus-2 has affected not only older children,...
SourceID doaj
gale
crossref
wolterskluwer
SourceType Open Website
Aggregation Database
Index Database
Publisher
StartPage 145
SubjectTerms C-reactive protein
Coronaviruses
Ferritin
Fibrin
Health aspects
immunomodulation
Infants
Infection
intravenous immunoglobulin
kawasaki disease
multisystem inflammatory syndrome in children
Natriuretic peptides
Original Article
SummonAdditionalLinks – databaseName: Medknow Open Access Journals
  dbid: W3E
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSAgJIZ7qloJ8QAKEDIlfcY7LimqLtKhiKfRm-SktaBPU3bZ_oT-7Yzstuwc4cYkSx3GcfDOescczg9ArUDqjjzYSYWtLeBCeKBskUSBKZGOM8DmYzuyLnB7zzyfiZAiTk3xhNuz3vK7Yh0X3c7l6n48aiEVTdhvdoQ1I5eQ9wv6sp1QgaWVOLVKBhCVUKV58ZP7SzJYcyuH6bwbl-xd9slSvfuWN6hvi5uAhejDoiXhcgH2EboXuMbo7GyzhT9DlUUm2jfuIsxNtCcmMD7sIGC-z7RzPh3AEeNHhyeC1jd_MDudk8jaVQeW0DSadZvsNFAC54OK6iEE1xPM0X_b4hznPb5qPv8Kz_XdC8VFafV4u3FN0fPDp22RKhqwKxLGmWREpIgxwrK2ZcsGDNiQr7lXtUiguR5nzwRnPhBeMBhNaESXlKgBytWi88ow9Qztd34VdhCtLTUxp8FqmODMxXUpnWmMsFyAGR-jd9T_Wv0vwDA2TjoSILlhsIjJCHxMMNzVT4OtcAPSgBz7SVUOtsUGFICO3obUqNtI5XnvTxMb6EXqdQNSJPdenxpnBywA6nEDR42Q3lK1soXP7WzWBrdzW7ekWGehlcU_8xwfANEroAX3dR32N_t7_a-o5ukdBqyr7hffRzvr0LLwArWhtX2Z2uAJXWA9W
  priority: 102
  providerName: Wolters Kluwer Health
Title Profile of Multisystem Inflammatory Syndrome in Children (MIS-C) in Infants in North India during the Second Wave of SARS-CoV-2 Pandemic
URI https://doi.org/10.4103/injms.injms_196_23
https://doaj.org/article/072babe8ee6f4be9b8f76cc41da7f7bd
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA_ShyKI1C88rZIHQUVid_O12cfr0XIVTopnbd9CPuEqtyu9q_4L_bM7Sbbl7kVffAm72Syb5DfJzOxkZhB6B0Jn9NFGImxtCQ_CE2WDJApYiWyMET4H05l9ldMz_uVCXGyk-kpnwkp44DJxB1VDrbFBhSAjt6G1KjbSOV5708TG-rT7Vm21oUzlPRj4rsyJRirgt4QqxYvHDK8rdrDoLperz7nUQIGasi2ulIP332_Rj_70yW69-pmPrW8wn-M99HiQGvG49PYJehC6p2h3NtjFn6Gb05J6G_cRZ5faEqAZn3QREF9mSzqeD8EJ8KLDk8GHG3-YnczJ5GOqg8bpUEy6zNYcqADiwcWREYOgiOdJe_b43PzOX5qPv8G7_Q9C8Wn6F71cuOfo7Pjo-2RKhhwLxLGmWREpImx3rK2ZcsGDbCQr7lXtUmAuR5nzwRnPhBeMBhNaESXlKgCOtWi88oy9QDtd34WXCFeWmpiS4rVMcWZiupXOtMZYLoApjtCnuznWv0ooDQ0qSEJEFyw2ERmhwwTDfcsUBjtXAHHogTj0v4hjhN4nEHVarOsr48zgcwAdTqDocbIiyla20Ln9rZawyNzW4-kWGehlcVb8ywBAqRJ6QF_3Ud-h_-p_DOw1ekhBuirnhvfRzvrqOrwB6Wht3-aFAOU5O7oFCCoSxw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Profile+of+Multisystem+Inflammatory+Syndrome+in+Children+in+Infants+in+North+India+during+the+Second+Wave+of+SARS-CoV-2+Pandemic&rft.jtitle=Indian+journal+of+medical+specialities&rft.au=Kumar%2C+Ashna&rft.au=Maheshwari%2C+Anu&rft.au=Mahajan%2C+Akanksha&rft.au=Mahto%2C+Deonath&rft.date=2024-07-01&rft.pub=Medknow+Publications+and+Media+Pvt.+Ltd&rft.issn=0976-2884&rft.volume=15&rft.issue=3&rft.spage=145&rft_id=info:doi/10.4103%2Finjms.injms_196_23&rft.externalDocID=A819569697
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0976-2884&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0976-2884&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0976-2884&client=summon